BIO Elects New Officers, Welcomes Nine New Board Members

CHICAGO--(BUSINESS WIRE)-- The Board of Directors of the Biotechnology Industry Organization (BIO) today elected a new slate of officers and nine new board members at BIO’s 2010 International Convention.

“Now more than ever, the inventive, savvy minds joining BIO’s board are needed to ensure that the industry has strong leadership today and an even more promising future on the horizon,” said BIO President and CEO Jim Greenwood. “Each of these individuals brings vision, energy and experience to BIO and the industry it represents.”

The members of the Executive Committee of BIO’s Board of Directors are:

 

Stephen Sherwin, MD, Full Board Chair, and Chair of the Health Section*

Chairman, Ceregene, Inc.
 

Mark Skaletsky, Treasurer*

Chairman, Neurophage Pharmaceuticals
 

Fabrizio Bonanni, Dr. Chem., Secretary*

Executive Vice President, Operations, Amgen, Inc.
 

Joshua Boger, PhD, Immediate Past Chair

Founder and Member of the Board, Vertex Pharmaceuticals Incorporated
 

Ron Cohen, MD, Chair of the Emerging Companies Section*

President & CEO, Acorda Therapeutics
 

Paul Hastings, Vice Chair of the Emerging Companies Section

President & CEO, OncoMed Pharmaceuticals, Inc.
 

Joachim Schneider, PhD, Chair of the Food & Agriculture Section*

Head of BioScience, Bayer CropScience, Inc.
 

Barbara Wells, PhD, Vice Chair of the Food & Agriculture Section

President & CEO, ArborGen, LLC
 

H. Thomas Watkins, Vice Chair of the Health Section*

President & CEO, Human Genome Sciences, Inc.
 

Tjerk de Ruiter, Chair of the Industrial & Environmental Section*

CEO, Genencor®: A Danisco Division
 

Vice Chair of the Industrial & Environmental Section

(To be determined later in the week)
 

Ian Clark, At Large

CEO & Head of North American Commercial Operations, Genentech, Inc.
 

Douglas Doerfler, At Large

President & CEO, MaxCyte, Inc.
 

Fereydoun Firouz, At Large

President & CEO, EMD Serono, Inc.
 

Rachel King, At Large

President & CEO, GlycoMimetics, Inc.
 

Richard Pops, At Large

Chairman, President & CEO, Alkermes, Inc.
 

David Pyott, At Large

Chairman & CEO, Allergan, Inc.
 
*also serves as an Officer of the Full BIO Board of Directors
 

BIO’s Board of Directors is composed of members of the Governing Boards for each of BIO’s four sections: Health, Emerging Companies, Industrial & Environmental and Food & Agriculture.

The new members of BIO’s Board of Directors are:

 

BJ Bormann, PhD, Senior Vice President & Global Head of Business Development,

Boehringer Ingelheim
(also serves on BIO’s Health Section Governing Board)
 

Peter Greenleaf, President, MedImmune

(also serves on BIO’s Health Section Governing Board)
 

Jonathan Leff, Managing Director, Health Care, Warburg Pincus, LLC

(also serves on BIO’s Emerging Companies Section Governing Board)
 

Jan Lundberg, PhD, Executive Vice President, Science and Technology, and President of

Lilly Research Laboratories, Eli Lilly and Company
(also serves on BIO’s Health Section Governing Board)
 

Stuart Peltz, PhD, President & CEO, PTC Therapeutics, Inc.

(also serves on BIO’s Emerging Companies Section Governing Board)
 

Carlos Riva, President, CEO and Director, Verenium Corporation

(also serves on BIO’s Industrial & Environmental Section Governing Board)
 

Jay Siegel, MD, Chief Biotechnology Officer and Global Head, Regulatory Affairs,

Johnson and Johnson
(also serves on BIO’s Health Section Governing Board)
 

Christopher Standlee, Executive Vice President, Institutional Relationships and Government

Affairs, Abengoa Bioenergy US Holding, Inc.
(also serves on BIO’s Industrial and Environmental Section Governing Board)
 

Hugh Welsh, Vice President & General Counsel, DSM North America

(also serves on BIO’s Industrial and Environmental Section Governing Board)
 

BIO is the world's largest organization representing the global biotechnology community, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. Corporate members range from entrepreneurial companies developing a first product to Fortune 500 multinationals, state and regional biotech associations, service providers to the industry, and academic centers. The mission of BIO is to be the champion of biotechnology and the advocate for its member organizations - both large and small.

Brief History

BIO was created in 1993 through the merger of the Association of Biotechnology Companies and the Industrial Biotechnology Association. The goal was for the entire industry, from young startups to established companies, to speak with one voice for the industry on important policy issues.

Since BIO was formed, it has been an effective public policy advocate. Specifically, BIO has:

  • Successfully advocated for an FDA pathway for the regulatory review and approval of biosimilars.
  • Successfully advocated for the Therapeutic Discovery Project Tax Credit to encourage investments in new therapies.
  • Ensured that reforms to Sarbanes-Oxley led to reduced burdens of compliance, taking into account biotech companies' size and risk.
  • Led efforts that have resulted in the establishment of bioscience economy development initiatives in virtually every state and territory.
  • Successfully advocated for aggressive, but realistic, targets for biofuels production, including key incentives for continued development of biotech-based fuels.
  • Advocated for biotech crops. Since their introduction in 1996, biotech crops have increased productivity and global farm income by $44.1 billion.
  • Advanced finalization of the FDA risk assessment on the safety of livestock cloning.
  • Achieved timely reauthorizations of the Prescription Drug User Fee Act (PDUFA) legislation consistent with BIO's principles.
  • Successfully advocated for Farm Bill policy options that will now accelerate the commercialization of next generation biofuels and bio-based products.
  • Successfully advocated for the enactment of FDA reform in the 1997 Food and Drug Administration Modernization Act.

Specific issues may have changed over the years, but our BIO’s core mission of fostering biotechnology innovation through advocacy, business development and communications remains the same.



CONTACT:

Biotechnology Industry Organization (BIO)
Ellen Dadisman, 202-312-9299
[email protected]

KEYWORDS:   United States  North America  Illinois

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.